Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics

Postgraduate Medicine
Leslie Citrome


Three new second-generation antipsychotics were approved by the US Food and Drug Administration in 2009 and 2010: iloperidone, asenapine, and lurasidone. All 3 agents are approved for the treatment of acute schizophrenia in adults, and asenapine is also approved for the maintenance treatment of schizophrenia and as a monotherapy or as an adjunct to lithium or valproate for the treatment of bipolar manic or mixed episodes. The expectation is that these new agents will be less problematic regarding treatment-emergent weight gain and metabolic disturbances, which unfortunately can occur with several other second-generation antipsychotics. Asenapine is a sublingual preparation, in contrast to iloperidone and lurasidone, which are swallowed. Iloperidone and asenapine are dosed twice daily, in contrast to lurasidone, which is dosed once daily with food. Both asenapine and lurasidone can be initiated at a dose that is possibly therapeutic, but iloperidone requires 4 days of titration to reach its recommended target dose range. Although both asenapine and lurasidone can be associated with dose-related treatment-emergent akathisia, iloperidone is essentially free of extrapyramidal adverse effects or akathisia throughout its recommended ...Continue Reading


Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Aug 31, 2011·Current Psychiatry Reports·Marsal Sanches, Jair C Soares
Jun 13, 2013·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Aug 9, 2013·The Journal of Clinical Investigation·Shijin YinHongzhen Hu
Jun 10, 2011·Neuropsychiatric Disease and Treatment·Leslie Citrome
Oct 2, 2012·Annual Review of Medicine·Herbert Y Meltzer
Feb 16, 2012·Expert Opinion on Drug Metabolism & Toxicology·Jose de LeonEdoardo Spina
Sep 29, 2011·Perspectives in Psychiatric Care·Norman L KeltnerJoan S Grant
Jun 28, 2013·The Journal of Dermatological Treatment·Xi TanSteven R Feldman
Mar 31, 2012·General Hospital Psychiatry·Amaia López de TorreJuan Medrano
Feb 19, 2013·Neuropharmacology·Lindsay N CatesPeter B Hedlund
Jun 28, 2016·Expert Opinion on Drug Safety·L OrsoliniD De Berardis
Mar 1, 2012·Expert Review of Neurotherapeutics·Joshua T Kantrowitz, Leslie Citrome
Nov 15, 2012·Therapeutic Drug Monitoring·Lisbeth PatteetHugo Neels
Jan 15, 2015·Journal of Clinical Psychopharmacology·Michelle A Worthington, Rif S El-Mallakh


Jul 14, 2007·CNS Drug Reviews·William M Greenberg, Leslie Citrome
Oct 27, 2007·The Journal of Clinical Psychiatry·Steven G PotkinJohn Panagides
May 6, 2008·Journal of Clinical Psychopharmacology·Peter J WeidenCurt D Wolfgang
May 6, 2008·Journal of Clinical Psychopharmacology·Steven G PotkinCurt D Wolfgang
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Leslie Citrome
Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Aug 12, 2009·Advances in Therapy·Leslie Citrome
Aug 12, 2009·Journal of Pain & Palliative Care Pharmacotherapy·U.S. Food and Drug Administration

Related Concepts

Metabolic Process, Cellular
Antipsychotic Effect
Lithium Measurement
Adverse Effects

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.